HB 291 prevents health insurers in Louisiana from penalizing hospitals or clinics (participating healthcare facilities) solely because another provider at that facility - like a doctor or specialist - is dropped from the insurer's network. The bill directly affects healthcare facilities that coordinate patient care with multiple providers, ensuring they won’t face payment cuts or contract terminations due to a partner provider’s network status. Key provisions ban insurers from reducing payments or ending agreements with facilities based on another provider’s network exclusion, and require that any contract clauses attempting to override this rule are void. This policy change aims to stabilize provider relationships and care continuity for patients.
HB 766 requires health insurers in Louisiana to cover orally administered anti-cancer medications on the same terms as intravenously administered ones. It prohibits insurers from imposing higher copays, deductibles, or prior authorizations for oral medications compared to IV treatments, and bans programs that ignore drug discounts (like "accumulator" programs). The bill caps out-of-pocket costs for oral anti-cancer drugs at $100 per prescription and ensures cost-sharing counts toward annual out-of-pocket maximums. It applies to most health plans but excludes limited-benefit policies, high-deductible plans with HSAs, and self-funded ERISA plans. This directly affects cancer patients and insurers by reducing financial barriers to oral medication access.
SB 255 requires Medicaid-funded behavioral health providers in Louisiana to ensure staff delivering psychosocial rehabilitation (PSR) services hold at least a bachelor's degree in specific fields like counseling, social work, or psychology. This affects all licensed providers seeking Medicaid reimbursement for PSR services. The bill mandates these educational qualifications as a condition for continued reimbursement, updating existing Medicaid eligibility rules. The measure is pending legislative review and would not take effect until enacted.
SB 236 requires the Louisiana Department of Health to annually review Medicaid coverage for medications and treatments for chronic and rare kidney diseases, ensuring they meet patient needs. It mandates public input during these reviews and directs the department to partner with kidney disease organizations to boost education and early screening. The bill also requires an annual report to the legislature by January 15 each year, detailing review findings and recommendations. This affects Medicaid enrollees diagnosed with kidney disease in Louisiana by improving access to appropriate care and promoting early detection. The law focuses on systematic reviews and transparency, not changing Medicaid eligibility or funding.
SB 169 requires health insurance plans in Louisiana to cover biomarker testing for patients needing personalized medical treatment, such as cancer care guided by genetic markers. It defines "clinical utility" through specific criteria to ensure tests are covered without unnecessary hurdles. The law prevents insurers from denying coverage based on laboratory classifications or unrelated credentialing, ensuring the test itself - not the lab - is the focus of coverage. This directly affects patients seeking biomarker tests and insurers, reducing the need for repeated biopsies by mandating seamless coverage.
SB 273 establishes new requirements for hospice care provided in non-hospice inpatient facilities like nursing homes and assisted living centers in Louisiana. It mandates written care plans for hospice patients detailing providers, care responsibilities, and family contacts; requires facilities to notify hospice providers and families during transfers; and creates patient logs tracking hydration/nutrition decisions and family communication. The bill directly affects hospice patients, their families, and facility staff by clarifying accountability and communication protocols during care. The Louisiana Department of Health will oversee compliance, investigate complaints, and enforce penalties for violations of these provisions.
HB 676 prohibits paying or receiving money for referring patients to substance abuse, mental health, or substance use disorder treatment facilities, defining this practice as "body brokering." It bans kickbacks tied to referral volume, treatment duration, or service type, but allows fixed payments unrelated to these factors. Violators face up to 5 years in prison, $50,000 fines, license suspension, or civil penalties. The law directly affects health care providers, facilities, and entities involved in patient referrals for substance use disorder treatment.
SB 311 updates Louisiana's rules for organ and tissue donations after death. It clarifies who can authorize donations (including family members with legal documents), creates new systems for tracking both donation authorizations and refusals via state registries, and defines key terms like "donor registry" to standardize procedures. These changes directly affect donors, hospitals, organ procurement organizations, and medical teams handling donations. The bill modernizes existing law without altering donation policies, focusing on clearer legal processes for families and healthcare providers.
HB 95 limits the amount a person can recover for medical expenses after a car accident if they had health insurance but didn't use it. It caps compensation at what their health insurance would have paid for those medical costs. This applies to standard car accident claims but does not affect workers' compensation cases under Louisiana law. The bill ensures health insurance coverage must be utilized before seeking full recovery for accident-related medical bills.
SB 30 prohibits Louisiana state agencies and licensing boards from banning telehealth services for evaluating, diagnosing, or treating obesity and related metabolic conditions. It directly affects licensed healthcare providers who use telehealth to deliver these services. The bill requires that providers may prescribe FDA-approved or compounded noncontrolled medications via telehealth while operating within their license scope and standard of care. This policy change removes regulatory barriers to telehealth for these specific conditions, without altering existing licensure requirements.